摘要
目的:观察bcl-2在恶性淋巴瘤患者瘤细胞中的表达,并分析其与预后的关系。方法:SABC免疫组化法检测bcl-2在恶性淋巴瘤患者和非肿瘤患者细胞中的表达,分析二者之间的差别,并分析恶性淋巴瘤患者阳性表达和阴性表达间完全缓解率(CR)的差别。结果:bcl-2在恶性淋巴瘤患者肿瘤细胞中的表达明显高于非肿瘤对照者(P<0.05),bcl-2阳性表达的恶性淋巴瘤患者的完全缓解率与阴性表达者的差异无显著性(P>0.05)。结论:bcl-2的阳性表达可能是恶性淋巴瘤对药物不敏感的原因之一,可作为判断恶性淋巴瘤患者预后的指标之一,对判断恶性淋巴瘤患者的预后更有意义。
Objective：To investigate the expression of bcl--2 in malignant lymphoma and analyze the relationship between the expression of bcl- 2 and the clinical significance. Methods： By using the immunohistochemical technique we detected the expression of bcl--2 in the untreated malignant lymphoma patient＇s tumor cells and the non--tumor patient＇s lymph cells, and analyzed the difference of CR rate between the patients with positive effect and negative effect. Results： The expression of bcl- 2 in lymphoma cells was significantly higher than that in the non--tumor lymph cells （P 〈 0. 05）. The CR rate of the patients with bcl- 2 negative expression wasn＇t higher than that of the patients with positive expression （P 〉 0.05）. Conclusion ：It is possible that the expression of bcl--2 influences upon the clinical effect,which might have clinical significance in prcdicting the prognosis in lymphoma.
出处
《黑龙江医药科学》
2008年第3期25-26,共2页
Heilongjiang Medicine and Pharmacy
